Endothelial dysfunction in neuroprogressive disorders-causes and suggested treatments

Area of Science:

• Cardiovascular Biology
• Neuroscience
• Molecular Medicine

Background:

• Systemic inflammation, oxidative stress, and mitochondrial dysfunction can lead to endothelial dysfunction and atherosclerosis, independent of cholesterol levels.
• Key molecular regulators of endothelial cell function include PECAM-1, VE-cadherin, VEGFRs, and signaling pathways like MAPK/ERK and NF-κB.
• Platelet activation, xanthene oxidase, and myeloperoxidase play significant roles in endothelial cell dysfunction.

Purpose of the Study:

• To examine the molecular mechanisms linking systemic inflammation, oxidative stress, and mitochondrial dysfunction to endothelial dysfunction.
• To describe the roles of various molecular players in endothelial cell regulation and dysfunction.
• To explore the application of these mechanisms to neuroprogressive disorders and identify potential treatment strategies.

Main Methods:

• Review and synthesis of existing literature on molecular pathways involved in endothelial function and dysfunction.
• Detailed description of key molecular players and their roles in cellular processes.
• Application of molecular insights to understand endothelial dysfunction in major depressive disorder, bipolar disorder, and schizophrenia.

Main Results:

• Identified critical molecular players such as PECAM-1, NF-κB, eNOS, and miRNAs in endothelial cell regulation.
• Elucidated the contribution of reactive oxygen species (ROS), reactive nitrogen species, and pro-inflammatory cytokines to endothelial dysfunction.
• Highlighted the impact of mitochondrial dysfunction, redox imbalance, and specific enzymes like myeloperoxidase and xanthene oxidase.

Conclusions:

• Molecular mechanisms of endothelial dysfunction are linked to neuroprogressive disorders like depression and schizophrenia.
• Potential treatment strategies can be developed based on mitigating inflammation, oxidative stress, and mitochondrial dysfunction.
• Targeting specific molecular pathways offers promise for managing endothelial dysfunction in neurological conditions.